Scarica l'app Stockscreener
1.38
3.76%
0.05
Dopo l'orario di chiusura:
1.35
-0.03
-2.17%
Fibrobiologics Inc Borsa (FBLG) Ultime notizie
Exclusive: FibroBiologics moves forward with human trial for diabetic foot ulcer therapy - MSN
FibroBiologics, Inc. Announces Reverse Stock Split and Certificate Amendment – SEC Form 8-K Filing Summary - Minichart
FibroBiologics Implements One-for-Twenty Reverse Stock Split - tipranks.com
FibroBiologics (NASDAQ: FBLG) completes 1:20 reverse stock split - Stock Titan
FibroBiologics closes $3M public offering with warrants By Investing.com - Investing.com Canada
FibroBiologics Announces Closing of $3 Million Public Offering - Sahm
Fibrobiologics announces closing of $3 million public offering - MarketScreener
FibroBiologics Closes $3M Public Offering - National Today
FibroBiologics Announces Public Offering and Warrant Agreements - tipranks.com
FibroBiologics Raises $2.5 Million Net in Public Offering Priced at $1.32, Adds Warrants Upside - TradingView
FibroBiologics (NASDAQ: FBLG) closes $3M stock and warrant offering - Stock Titan
Latest FBLG NewsFibroBiologics Announces Closing of $3 Mill... - Stock Titan
FibroBiologics, Inc. Common Stock (FBLG) Stock Price Today & Analysis - Gotrade
FibroBiologics (NASDAQ: FBLG) sells shares and warrants; reverse split in place - Stock Titan
FibroBiologics, Inc. Announces Pricing of Public Offering for 2.27 Million Shares and Warrants - Moomoo
FBLG: Advancing Fibroblast Therapy on Multiple Fronts - Yahoo Finance
FibroBiologics manufactures first batch of CYWC628 drug product for trials - tipranks.com
FibroBiologics prices $3M public offering at $1.32/share By Investing.com - Investing.com Australia
FibroBiologics prices $3M public offering at $1.32/share - Investing.com
FibroBiologics Announces Pricing of $3 Million Public Offering - The Manila Times
After a $3M raise, FibroBiologics targets working capital needs - Stock Titan
FibroBiologics Completes Manufacturing of Diabetic Foot Ulcer Drug - National Today
FibroBiologics completes first CYWC628 batch for clinical trials By Investing.com - Investing.com India
FibroBiologics completes first CYWC628 batch for clinical trials - Investing.com
FibroBiologics Announces Successful Manufacturing of CYWC628 Drug Product to Support Upcoming Diabetic Foot Ulcer Clinical Trial - The Manila Times
EXCLUSIVE: FibroBiologics Moves Forward With Human Trial For Diabetic Foot Ulcer Therapy - Benzinga
Signal Recap: How do insiders feel about FibroBiologics Inc2026 Volatility Report & Low Risk High Win Rate Picks - baoquankhu1.vn
Short Squeeze: Is FibroBiologics Inc benefiting from interest rate changesQuarterly Growth Report & Technical Pattern Alert System - baoquankhu1.vn
FibroBiologics prices combined unit offering at $4.40 and 1-for-20 reverse split to regain Nasdaq compliance - MSN
FibroBiologics (FBLG) files S-1 for $4.3M stock and warrant sale - Stock Titan
Revenue Check: How do insiders feel about FibroBiologics IncQuarterly Portfolio Summary & Verified High Yield Trade Plans - baoquankhu1.vn
FibroBiologics To Carry Out 1-for-20 Reverse Stock Split On March 30th, 2026 - Moomoo
FibroBiologics Announces 1-20 Reverse Stock Split - National Today
D. Boral Capital downgrades FibroBiologics stock rating to hold By Investing.com - in.investing.com
D. Boral Capital downgrades FibroBiologics stock rating to hold - Investing.com
FibroBiologics announces 1-for-20 reverse stock split By Investing.com - Investing.com Australia
FibroBiologics to implement 1-for-20 reverse stock split to meet Nasdaq requirement - MSN
FibroBiologics stock tumbles on reverse stock split plan By Investing.com - Investing.com South Africa
FibroBiologics stock tumbles on reverse stock split plan - investing.com
FibroBiologics Announces Reverse Stock Split to Regain Compliance with Nasdaq's Bid Price Requirement - Bitget
FibroBiologics announces 1-for-20 reverse stock split - Investing.com
FibroBiologics shares are trading lower after... - Benzinga
FibroBiologics announces reverse stock split to regain compliance with Nasdaq's bid price requirement - MarketScreener
To keep Nasdaq listing, FibroBiologics enacts 1-for-20 split - Stock Titan
FibroBiologics (ticker: FBLG) recently announced a significant move: the company will conduct a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement. - Bitget
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
If You Invested $1,000 in Fibrobiologics (FBLG) - Stock Titan
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):